Abstract：
OBJECTIVE: The present study aims to establish the role of serum CGRP and SP levels in the disease pathophysiology in patients with dialysis headache not accompanied by primary or secondary headaches, and also whether there is a correlation between these vasoactive peptides and the severity of headache.
METHODS: This study was designed as prospective and multicenter. A total of 30 dialysis headache patients and 30 patients without headache as the control group in the Nephrology outpatient clinics which implement similar dialysis procedures were included in the study. Blood samples were taken from all the patients before hemodialysis, and post-hemodialysis samples were collected. CGRP and SP contents in serum samples were measured using the ELISA method with detection kits.
RESULTS: A total of 60 patients were included in the study with 17 female and 13 male patients in the dialysis headache group and 18 female and 12 male patients in the control group, and there were no significant differences in sex and age between the groups. CGRP levels in the headache group were found to be significantly higher compared with the control group both before and after hemodialysis. Furthermore, pre-hemodialysis CGRP levels were significantly higher than post-hemodialysis CGRP levels in both the headache and control groups. Serum SP levels in the headache group were found to be higher compared with the control group both before and after hemodialysis, there was no significant difference between the groups. Even though SP levels in both groups decreased after hemodialysis, there was again no significant difference between the groups. No correlation was found between the patients\' severity of headache and serum CGRP and SP levels.
CONCLUSIONS: This study concludes that CGRP and SP, even though the latter is not statistically significant, play a role in the pathophysiology of the dialysis headache, and further studies with a larger and more specific patient population may reveal the relationship between the neuropeptides and dialysis headache more clearly.
METHODS: This study was designed as prospective and multicenter. A total of 30 dialysis headache patients and 30 patients without headache as the control group in the Nephrology outpatient clinics which implement similar dialysis procedures were included in the study. Blood samples were taken from all the patients before hemodialysis, and post-hemodialysis samples were collected. CGRP and SP contents in serum samples were measured using the ELISA method with detection kits.
RESULTS: A total of 60 patients were included in the study with 17 female and 13 male patients in the dialysis headache group and 18 female and 12 male patients in the control group, and there were no significant differences in sex and age between the groups. CGRP levels in the headache group were found to be significantly higher compared with the control group both before and after hemodialysis. Furthermore, pre-hemodialysis CGRP levels were significantly higher than post-hemodialysis CGRP levels in both the headache and control groups. Serum SP levels in the headache group were found to be higher compared with the control group both before and after hemodialysis, there was no significant difference between the groups. Even though SP levels in both groups decreased after hemodialysis, there was again no significant difference between the groups. No correlation was found between the patients\' severity of headache and serum CGRP and SP levels.
CONCLUSIONS: This study concludes that CGRP and SP, even though the latter is not statistically significant, play a role in the pathophysiology of the dialysis headache, and further studies with a larger and more specific patient population may reveal the relationship between the neuropeptides and dialysis headache more clearly.
摘要：
目的：本研究旨在确定血清CGRP和SP水平在不伴有原发性或继发性头痛的透析性头痛患者的疾病病理生理中的作用。以及这些血管活性肽与头痛的严重程度之间是否存在相关性。
方法：本研究设计为前瞻性和多中心。在肾内科门诊诊所中，共有30名透析头痛患者和30名无头痛患者作为对照组，这些患者实施了类似的透析程序。血液样本取自血液透析前的所有患者，并收集血液透析后样本。用ELISA法检测血清样品中CGRP和SP含量。
结果：共纳入60例患者，其中透析头痛组17例女性患者，13例男性患者，对照组18例女性患者，12例男性患者，两组之间的性别和年龄没有显着差异。发现头痛组的CGRP水平在血液透析前后均明显高于对照组。此外，在头痛组和对照组中,血液透析前CGRP水平均显著高于血液透析后CGRP水平.发现头痛组血液透析前后血清SP水平均高于对照组，组间无显著差异。尽管血液透析后两组的SP水平均下降，两组间再次无显著差异.患者头痛严重程度与血清CGRP和SP水平无相关性。
结论：本研究得出结论，CGRP和SP，尽管后者在统计上并不显著，在透析头痛的病理生理学中发挥作用，对更大和更具体的患者群体的进一步研究可能更清楚地揭示神经肽和透析头痛之间的关系。
方法：本研究设计为前瞻性和多中心。在肾内科门诊诊所中，共有30名透析头痛患者和30名无头痛患者作为对照组，这些患者实施了类似的透析程序。血液样本取自血液透析前的所有患者，并收集血液透析后样本。用ELISA法检测血清样品中CGRP和SP含量。
结果：共纳入60例患者，其中透析头痛组17例女性患者，13例男性患者，对照组18例女性患者，12例男性患者，两组之间的性别和年龄没有显着差异。发现头痛组的CGRP水平在血液透析前后均明显高于对照组。此外，在头痛组和对照组中,血液透析前CGRP水平均显著高于血液透析后CGRP水平.发现头痛组血液透析前后血清SP水平均高于对照组，组间无显著差异。尽管血液透析后两组的SP水平均下降，两组间再次无显著差异.患者头痛严重程度与血清CGRP和SP水平无相关性。
结论：本研究得出结论，CGRP和SP，尽管后者在统计上并不显著，在透析头痛的病理生理学中发挥作用，对更大和更具体的患者群体的进一步研究可能更清楚地揭示神经肽和透析头痛之间的关系。
